Investigators identified that PD-L1 on CTCs not only assisted in distinguishing responders (Rs), non-responders (NRs), or pseudoprogressors in the early stage of ICI administration, but also had an association with prognosis in advanced melanoma [31]. The gene discussed is CD274; the disease is melanoma.